ClinicalTrials.gg
TerminatedNCT00975806Updated Nov 25, 2019Results posted

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

A Phase 1/2 interventional study of Lenalidomide and Sunitinib in Renal Cell Carcinoma, sponsored by Celgene. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing sunitinib in Carcinoma, Renal Cell — 3 open to participants now, 6 under way, none of them phase 3. Sunitinib · Carcinoma, Renal Cell.

Enrollment
57th of 78
16 · median 33
Started
2009
with 9 others
Phase 1/2
6 of 78
1 open now
Registered
38th of 78
by date

Among the 78 studies testing sunitinib in Carcinoma, Renal Cell, this one is the 57th largest by enrollment, is one of 10 that started in 2009, is one of 6 in phase 1/2, and was the 38th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

3 of the 78 studies testing sunitinib in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sunitinib

Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing sunitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Renal Cell Carcinoma.
  2. (ECOG) performance status of ≤ 1.

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy.
  2. Prior treatment with lenalidomide, thalidomide, pomalidomide, or sunitinib.
  3. Laboratory values outside normal ranges.
  4. Myocardial infarction (MI) within past 12 months.
  5. Current congestive heart failure.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort A

    Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle

    Drug: Lenalidomide · Drug: Sunitinib

  • Experimental
    Cohorts F and G

    Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle

    Drug: Lenalidomide · Drug: Sunitinib

Interventions

  • Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination

    Also known as: CC-5013, Revlimid

  • Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G

    Also known as: Sutent

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD)

    The MTD of lenalidomide in combination with sunitinib was defined as the highest dose level at which no more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). Dose limiting toxicities were: • Inability to deliver Lenalidomide in Cycle 1 due to a drug-related toxicity resulting in: * Grade (GR) 3 or 4 non-hematological toxicity lasting for ≥ 14 days * Febrile neutropenia * Gr 4 neutropenia lasting for ≥ 7 days * Gr 4 thrombocytopenia The occurrence of one of the above drug-related toxicities resulting in a clinical and/or laboratory assessment being done within 7 days following the initial finding to examine the participants for resolution of the toxicity. Lack of resolution of the toxicities was considered a DLT. If ≤ 7 doses of lenalidomide or Sunitinib were missed in Cycle 1 due to non-drug related event, the participant data was to be included in the evaluation of dose escalation.

    Time frame: Within 21 days of first dose of treatment

  2. Phase 2: Tumor Response Rate According to Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

    Tumor response was to be evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was to be defined by RECIST 1.1 criteria: * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions. * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.

    Time frame: After at least 3 cycles of treatment

Secondary outcomes

  1. Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Lenalidomide and Sunitinib

    Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participants health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death

    Time frame: First day of study drug to within 28 days after the last dose of the last study drug; The duration of exposure to lenalidomide and sunitinib was 7.0 to 327 and 7.0 to 328 days respectively

  2. Phase 1 : Tumor Response Rate According to RECIST 1.1

    Tumor response was evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was evaluated using the Response Criteria Evaluation in Solid Tumors (RECIST 1.1) criteria: Treatment response includes both complete response and partial response * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir

    Time frame: Every 3 cycles; up to month 25

  3. Progression Free Survival (PFS)

    Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first.

    Time frame: Day 1 of study drug to disease progression or death

  4. Duration of Response

    Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR)

    Time frame: Day 1 of initial response date to progressive disease

  5. Overall Survival (OS)

    Overall survival was defined as the time from the start of study drug therapy to death.

    Time frame: Day 1 of study drug to death

07

Results

Posted Dec 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneCohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mg
Started574
Completed000
Not completed574
Withdrew: Adverse event212
Withdrew: Disease progression151
Withdrew: Withdrawal by subject100
Withdrew: Death010
Withdrew: Physician decision and disease related101

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD)

The MTD of lenalidomide in combination with sunitinib was defined as the highest dose level at which no more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). Dose limiting toxicities were: • Inability to deliver Lenalidomide in Cycle 1 due to a drug-related toxicity resulting in: * Grade (GR) 3 or 4 non-hematological toxicity lasting for ≥ 14 days * Febrile neutropenia * Gr 4 neutropenia lasting for ≥ 7 days * Gr 4 thrombocytopenia The occurrence of one of the above drug-related toxicities resulting in a clinical and/or laboratory assessment being done within 7 days following the initial finding to examine the participants for resolution of the toxicity. Lack of resolution of the toxicities was considered a DLT. If ≤ 7 doses of lenalidomide or Sunitinib were missed in Cycle 1 due to non-drug related event, the participant data was to be included in the evaluation of dose escalation.

Time frame:
Within 21 days of first dose of treatment
Reported as:
Number · mg
Phase 1: Maximum Tolerated Dose (MTD)
mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mg
Phase 1: Maximum Tolerated Dose (MTD)10
PrimaryPhase 2: Tumor Response Rate According to Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

Tumor response was to be evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was to be defined by RECIST 1.1 criteria: * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions. * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.

Time frame:
After at least 3 cycles of treatment

No measurements were reported for this outcome.

SecondaryPhase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Lenalidomide and Sunitinib

Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participants health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death

Time frame:
First day of study drug to within 28 days after the last dose of the last study drug; The duration of exposure to lenalidomide and sunitinib was 7.0 to 327 and 7.0 to 328 days respectively
Reported as:
Number · participants
Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Lenalidomide and Sunitinib
participantsCohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mg
Participants with at least 1 TEAE574
Participants with at least 1 serious TEAE342
≥ 1 TEAE leading to stopping lenalidomide222
≥ 1 TEAE leading to stopping sunitinib222
≥ 1 TEAE -> dose reduction/interrruption of Len564
≥ 1 TEAE dose reduction/interrruption of Sunitinib553
Participants with ≥1 TEAE related to lenalidomide574
Participants with ≥1 TEAE related to Sunitinib574
≥ 1 NCI CTC Gr 3 or higher TEAE564
≥ 1 NCI CTC Gr 3 or higher related to lenalidomide454
≥ 1 NCI CTC Gr 3 or higher related to Sunitinib454
≥ 1 serious TEAE related to lenalidomide220
≥ 1 serious TEAE related to sunitinib122
SecondaryPhase 1 : Tumor Response Rate According to RECIST 1.1

Tumor response was evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was evaluated using the Response Criteria Evaluation in Solid Tumors (RECIST 1.1) criteria: Treatment response includes both complete response and partial response * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir

Time frame:
Every 3 cycles; up to month 25
Reported as:
Number · participants
Phase 1 : Tumor Response Rate According to RECIST 1.1
participantsCohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mg
Complete Response000
Partial Response100
Stable Disease133
SecondaryProgression Free Survival (PFS)

Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first.

Time frame:
Day 1 of study drug to disease progression or death

No measurements were reported for this outcome.

SecondaryDuration of Response

Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR)

Time frame:
Day 1 of initial response date to progressive disease

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival was defined as the time from the start of study drug therapy to death.

Time frame:
Day 1 of study drug to death

No measurements were reported for this outcome.

Adverse events

Collected over Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A—3/5 (60%)5/5 (100%)
Cohort F—4/7 (57.1%)7/7 (100%)
Cohort G—2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCohort ACohort FCohort G
Atrial FibrillationCardiac disorders0/50/71/4
PancreatitisGastrointestinal disorders0/50/71/4
AnaemiaBlood and lymphatic system disorders1/50/70/4
LeukopeniaBlood and lymphatic system disorders1/50/70/4
NeutropeniaBlood and lymphatic system disorders1/50/70/4
ThrombocytopeniaBlood and lymphatic system disorders1/50/70/4
AstheniaGeneral disorders1/50/70/4
Device related infectionInfections and infestations1/50/70/4
Urinary Tract InfectionInfections and infestations1/50/70/4
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/51/70/4
Most frequent other events
Showing 10 of 104
Most frequent other events
EventCohort ACohort FCohort G
DiarrhoeaGastrointestinal disorders5/53/72/4
FatigueGeneral disorders3/57/74/4
NauseaGastrointestinal disorders4/54/73/4
DysgeusiaNervous system disorders4/54/71/4
LeukopeniaBlood and lymphatic system disorders2/51/73/4
AnaemiaBlood and lymphatic system disorders3/53/71/4
VomitingGastrointestinal disorders3/53/72/4
DehydrationMetabolism and nutrition disorders3/50/70/4
HypoalbuminaemiaMetabolism and nutrition disorders3/52/70/4
DizzinessNervous system disorders3/51/72/4

Baseline characteristics

Safety Population includes all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mgTotal
Mean55.0 ± 18.8457.1 ± 4.8857.3 ± 5.6256.5 ± 10.56
Age, Customized
Age, Customized(participants)Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mgTotal
≤65 years47415
>65 years1001
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mgTotal
Female2428
Male3328
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mgTotal
Caucasian (White)46414
Black or African American1001
Unknown0101
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mgCohort F: Lenalidomide 10mg and Sunitinib 37.5mgCohort G: Lenalidomide 15mg and Sunitinib 37.5mgTotal
0 = fully active44412
1 = restricted activity but ambulatory1304
3 (Limited Self-Care)0000
4 (Completely Disabled)0000
08

Study locations

3 sites
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Cleveland Clinic Main Campus
    Cleveland, Ohio 44195, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
09

References and documents

Publications

  • Rini B, Redman B, Garcia JA, Burris HA 3rd, Li S, Fandi A, Beck R, Jungnelius U, Infante JR. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol. 2014 Sep;25(9):1794-1799. doi: 10.1093/annonc/mdu212. Epub 2014 Jun 8. PubMed 24914044 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2009 to primary completion in Oct 2011, 25 months.

Results were first posted in Dec 2014, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2009
First posted
Sep 11, 2009
StartActual
Sep 1, 2009
Primary completionActual
Oct 1, 2011
CompletionActual
Oct 1, 2011
Results first posted
Dec 29, 2014
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00975806
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 11, 2009
Start date
Sep 1, 2009
Primary completion
Oct 1, 2011
Completion
Oct 1, 2011
Results posted
Dec 29, 2014
Last update
Nov 25, 2019

Study contacts

Debora Barton, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Sunitinib

Start the discussion